



CANNIDEX™

Advancing the Science of Topical CBD

The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX™. The efficacy of CANNIDEX™ has not been confirmed by FDA-approved research and CANNIDEX™ is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX™. The Federal Food, Drug and Cosmetic Act requires this notice.



CANNIDEX™

is different.

💧 *Not all hemp-derived CBD topicals are created equal.* Developed almost exclusively from pure hemp crystal (not oil), CANNIDEX™ is manufactured under stringent pharmaceutical-grade standards to deliver 1500 mg of CBD in a patented transdermal cream base that can be applied on the body and at the back of the neck at the hairline.¹⁻³ Because CANNIDEX™ contains only CBD—not THC—the compound has no psychoactive effect.^{1,4}

SAFETY-FOCUSED

Non-Systemic

Topicals are one of the safest ways to consume hemp-derived medications and may be the best option for certain pains or ailments. CBDs are not psychoactive and applying CANNIDEX™ to the skin will not result in a psychoactive effect.³⁻⁵

PURITY

99% Pure Solid Hemp Crystal

Unlike other topical CBD formulations, CANNIDEX™ is derived from 99% pure hemp crystals, not from hemp-CBD oils.¹

RIGOROUS MANUFACTURING

Pharmaceutical-Grade

CANNIDEX™ is produced in a state-of-the-art facility overseen by licensed pharmacists.

ODOR FREE

No cannabis-related smell

CANNIDEX™ is odorless and does not contain any artificial fragrances or dyes.

POTENCY

1500 mg Active CBD

CANNIDEX™ delivers 1500 mg of active CBD in each 50 mg topical formulation.¹

BEST-IN-CLASS DISPENSER

Precise Airless Technology

Patented airless dispenser delivers CANNIDEX™ in precise dosages with minimal waste in a self-sealing bottle to reduce contamination, dry-out and discoloration of formulation.

TARGETED DELIVERY

High-Grade Penetrating Base

A proprietary transdermal base safely delivers CANNIDEX™ through the skin with a clinically proven topical delivery system.¹⁻³

The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX. The efficacy of CANNIDEX has not been confirmed by FDA-approved research and CANNIDEX is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX. The Federal Food, Drug and Cosmetic Act requires this notice.

CANNIDEX™ Delivers CBD through Direct Effects™ – a novel patented non-systemic therapy using hemp-derived CBD^{3*}

NON-SYSTEMIC TOPICAL CREAM^{2,3}

Direct Effects™ is a topical regional neuro-affective (TRNA) therapy.

- 💡 Is designed to be applied to the BONATH region (Back of the Neck at the Hairline).
- 💡 Has a direct affect through free nerve-endings and peripheral nerve connections.
- 💡 Does not rely on systemic or cerebral blood flow for effect.

LACK OF SYSTEMIC SIDE EFFECTS^{2,3}

Direct Effects™ provides therapeutic benefit without systemic side effects or drug interactions.

- 💡 Side effects minimized without drug in systemic and cerebral blood flow.
- 💡 Drug-drug interactions and metabolism/excretion are negligible.
- 💡 May provide a benefit for those reluctant to expose themselves or dependents to cannabinoid stimulation with unknown long-term consequences.

RAPID THERAPEUTIC BENEFITS^{2,3}

Direct Effects™ provides rapid and prolonged drug effect— regional administration allows high tissue saturation of drug.

- 💡 Results within 15–30 minutes working through nerve connections.
- 💡 May have clinical benefits in conditions such as seizures.

“A ground-breaking topical drug therapy which treats neurologic and psychiatric conditions, including chronic pain, through direct nerve connections without limitations of blood flow; thereby providing rapid therapeutic benefits without concerns of systemic side effects and drug interactions.”³

RONALD AUNG-DIN, M.D

Inventor & Patents Holder
General Neurology & Neuropsychiatry
American Board of Psychiatry and Neurology
American Academy of Neurology

Direct Effects™ Topical CBD in Clinical Practice with Dr. Ronald Aung-Din

Neurologist, neuropsychiatrist and researcher Dr. Aung-Din is an expert in the field of topical delivery at the BONATH region for neurological conditions. With over 15 years of clinical research, he has garnered multiple patents for his novel approaches—including treatments for migraine and Parkinson's disease. He was one of the first neurologists certified to prescribe medical marijuana in the State of Florida.³

Dr. Ronald Aung-Din, MD has been using a Direct Effects™ topical hemp-derived CBD formulation. With only 1 to 2 pumps applied to the BONATH region, he has successfully treated patients for the following conditions in his practice ³:

- Seizures/Epilepsy
- Spasticity
- Encephalopathy (including lethargy, attentional problems, and cognition)
- Pain (including radiculopathy and neuropathy)
- Fibromyalgia
- Numbness/tingling
- Hypertension and autonomic dysfunction
- Parkinson's disease and tremors
- Insomnia
- Bell's palsy and facial nerve dysfunction
- Trigeminal neuralgia
- Hemi-facial spasms
- Autism/Asperger's
- Attention Deficit Disorder and Hyperactivity
- Anxiety/Mood Disorders/Social isolation
- Occipital neuralgia
- TMJ dysfunction related symptoms
- Headaches (migraine and tension)
- Peripheral neuropathy


*CANNIDEX Brands, LLC is a licensee of United States Patent Application No. 62126757, filed in March 2015 by inventor Ronald Aung-Din and currently pending with the USPTO. This patent covers the application of topical hemp derived CBD at the BONATH region through Direct Effects™. No FDA-approved clinical trials have been conducted with any Direct Effects™ CBD topical formulation.

The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX™. The efficacy of CANNIDEX™ has not been confirmed by FDA-approved research and CANNIDEX™ is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX™. The Federal Food, Drug and Cosmetic Act requires this notice.

Introduce Your Customers to
CANNIDEX™

Only CANNIDEX™ offers customers the purity of hemp crystal combined with the potency of 1500 mg active CBD in a patented transdermal cream base to safely deliver CBD where it's needed. CANNIDEX™ is competitively priced for customer accessibility.¹⁻³

For immediate information on purchasing and reordering, contact:



CANNIDEX™

Advancing the Science of Topical CBD

Learn more at CANNIDEX.com

REFERENCES: 1. Data on file 001. Cannidex Brands, LLC 2016. 2. Aung-Din R. Topical Regional Neuro-Affective (TRNA) Therapy: Novel Ground-Breaking Triptan Drug Delivery for Treating Migraines. *Drug Delivery Technology*. 2009; 9(9):44-51. 3. Data on file 002. Cannidex Brands, LLC 2016. 4. Volkow ND. NIH National Institute on Drug Abuse (NIDA). The Biology and Potential Therapeutic Effects of Cannabidiol. Available at: <https://www.drugabuse.gov/about-ni-da/legislative-activities/testimony-to-congress/2016/biology-potential-therapeutic-effects-cannabis>. Accessed March 1, 2016. 5. Americans for Safe Access. Guide to Using Medical Cannabis. Available at: http://www.safeaccessnow.org/using_medical_cannabis Accessed March 1, 2016.

The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX™. The efficacy of CANNIDEX™ has not been confirmed by FDA-approved research and CANNIDEX™ is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX™. The Federal Food, Drug and Cosmetic Act requires this notice.

©2016 CANNIDEX Brands, LLC. All rights reserved. Printed in USA/April 2016

CANNIDEX™ is a trademark of Cannidex Brands, LLC. Direct Effects™ is a trademark of AfGin Pharma, LLC



**10%
TOTAL RECOVERED FIBER**